These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 11976073)
21. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Plans-Rubió P Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391 [TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW; Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813 [TBL] [Abstract][Full Text] [Related]
25. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Karlson BW; Wiklund O; Palmer MK; Nicholls SJ; Lundman P; Barter PJ Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):212-7. PubMed ID: 27533947 [TBL] [Abstract][Full Text] [Related]
26. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487 [TBL] [Abstract][Full Text] [Related]
27. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Hirsch M; O'Donnell JC; Jones P Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502 [TBL] [Abstract][Full Text] [Related]
28. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504 [TBL] [Abstract][Full Text] [Related]
29. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results. Heintjes EM; Hirsch MW; van der Linden MW; O'Donnell JC; Stalenhoef AF; Herings RM Curr Med Res Opin; 2008 Aug; 24(8):2241-50. PubMed ID: 18578957 [TBL] [Abstract][Full Text] [Related]
30. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
31. Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. Hobbs FD; Southworth H Int J Clin Pract; 2005 Oct; 59(10):1171-7. PubMed ID: 16178985 [TBL] [Abstract][Full Text] [Related]
32. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124 [TBL] [Abstract][Full Text] [Related]
33. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW; Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429 [TBL] [Abstract][Full Text] [Related]
34. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129 [TBL] [Abstract][Full Text] [Related]
35. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558 [TBL] [Abstract][Full Text] [Related]
36. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. Edwards JE; Moore RA BMC Fam Pract; 2003 Dec; 4():18. PubMed ID: 14969594 [TBL] [Abstract][Full Text] [Related]
37. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis. Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264 [TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893 [TBL] [Abstract][Full Text] [Related]
39. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Bays HE; Davidson M; Jones MR; Abby SL Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026 [TBL] [Abstract][Full Text] [Related]
40. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. McKenney JM Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]